Clinical data near for Alzheimer’s antibodies from Roche and Lilly, while Cortexyme and Biohaven test small molecules.
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
One day after Biogen expands aducanumab trials, a canary in the coal mine, the rival crenezumab, fails in phase III.